Emcure Pharma Delivers Robust Performance Across All Businesses in Q1FY26: Satish Mehta
Emcure Pharmaceuticals reported strong financial results for the first quarter of FY26, demonstrating impressive growth in both domestic and international businesses.
Emcure Pharmaceuticals | 07/08/2025 | By Dineshwori | 265
Sanofi India, Emcure Sign Exclusive Distribution Partnership for Anti-Diabetic Drugs
Sanofi India Ltd. has entered into an exclusive distribution and promotion agreement with Emcure Pharmaceuticals for its oral anti-diabetic brands, including Amaryl and Cetapin, aiming to expand patient access and strengthen diabetes care across India.
Emcure Pharmaceuticals | 17/07/2025 | By Mrinmoy Dey | 194
Emcure Pharma Taps Industry Veteran R.S. Vasan to Lead India Business
Emcure Pharmaceuticals Ltd. has appointed R.S. Vasan as President – India Business and Senior Management Personnel (SMP).
Emcure Pharmaceuticals | 16/07/2025 | By Dineshwori | 233
Emcure Pharmaceuticals Launches its R&D Centre in Ahmedabad
The Emcure Research Centre (ERC) is strategically designed to enable breakthroughs in complex drug delivery systems, such as sustained-release formulations, liposomal injections and advanced dermal therapies.
Emcure Pharmaceuticals | 23/01/2025 | By Aishwarya | 581
Emcure Launches New Entity Emcutix Biopharmaceuticals for Dermatology Sector
As a part of this strategic initiative, Emcure's existing dermatology business will also operate under Emcutix.
Emcure Pharmaceuticals | 29/10/2024 | By Aishwarya | 703
Emcure Plans for Expansion and New Acquisitions with Upcoming IPO
Emcure Pharmaceuticals has been planning to expand its business as the upcoming initial public offering (IPO) will give the company access to new growth capital which it will use to fund inorganic growth and explore acquisitions.
Emcure Pharmaceuticals | 29/06/2024 | By Aishwarya | 1243
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy